Part,  Chapter, Paragraph

  1    I,     2.  4        |           incidence and prevalence rates, treatment and cure rates, and access
  2    I,     2.  4        |                hypertension detection and treatment, surgical interventions
  3    I,     2.  5        |                  indexation rules and the treatment of non contributory periods,
  4    I,     2. 10.  3    |                   forms needed for health treatment in another Member State.
  5    I,     2. 10.  4    |            product manufacture to patient treatment, is imperative to comply
  6   II,     5.  1.  1    |                   and within individuals. Treatment has become increasingly
  7   II,     5.  1.  1    |            patterns in time and different treatment. Certain medical conditions
  8   II,     5.  1.  3    |                   the disease, prescribed treatment, care, hospital and other
  9   II,     5.  1.  3    |            understand the disease and the treatment, cooperate with health care
 10   II,     5.  1.  3    |               This is an integral part of treatment and care.~Therapeutic patient
 11   II,     5.  1.  3    |             self-managing or adapting the treatment to their particular chronic
 12   II,     5.  1.  3    |                   families) to manage the treatment of their condition and prevent
 13   II,     5.  2.  1    |                   make CVD prevention and treatment a priority to reduce the
 14   II,     5.  2.  3    |                 behaviours, diagnosis and treatment.~The decline in mortality
 15   II,     5.  2.  4    |                healthy lifestyle and drug treatment for individuals at high
 16   II,     5.  2.  4    |          hypertension undergoing adequate treatment has not changed and is still
 17   II,     5.  2.  5    |                   mainly smoking, whereas treatment of individuals including
 18   II,     5.  2.  5    |                   the CVD risk increases; treatment targets for LDL cholesterol
 19   II,     5.  2.  5    |                 life-long pharmacological treatment with drugs must be considered.~
 20   II,     5.  2.  5    |             suggests that improvements in treatment (thrombolysis; aspirin;
 21   II,     5.  2.  6    |             suggests that improvements in treatment (thrombolysis; aspirin;
 22   II,     5.  2.  6    |                   high, a pharmacological treatment should be considered. All
 23   II,     5.  2.  6    |    antihypertensive classes available for treatment can be used, taking into
 24   II,     5.  2.  6    |                   R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators (
 25   II,     5.  2.  6    |                   of cholesterol-lowering treatment: prospective meta-analysis
 26   II,     5.  2.  6    |               risk factor: prevention and treatment. JAMA 275: 1571-1576.~Keys
 27   II,     5.  2.  6    |                   Blood Pressure Lowering Treatment Trialists' Collaboration (
 28   II,     5.  2.  7    |                   Education Program Adult Treatment Panel III Guidelines. J
 29   II,     5.  3.  2    |          providing comparative data about treatment patterns and outcomes, access
 30   II,     5.  3.  2    |                   and outcomes, access to treatment between social groups. To
 31   II,     5.  3.  2    |                  data, such as details on treatment, quality of life, hospitalisation
 32   II,     5.  3.  2    |               cancer screening and cancer treatment programmes:~· the EU should
 33   II,     5.  3.  2    |                   inequality of access to treatment for cancer patients and
 34   II,     5.  3.  6    |           possibly related to advances in treatment. Moreover, it is important
 35   II,     5.  3.  6    |                 availability of effective treatment (Coleman et al, 2003).~ ~
 36   II,     5.  3.  6    |                  access to diagnostic and treatment facilities, tumour-site-specific
 37   II,     5.  3.  7    |                 prevention, diagnosis and treatment, improving survival and
 38   II,     5.  3.  7    |             groups), to a more successful treatment of cancer patients due to
 39   II,     5.  3.  7    |             disease when too advanced for treatment, thus improve the quality
 40   II,     5.  3.  7    |              diagnosis, access to optimal treatment and investment in health
 41   II,     5.  3.  7    |                 is well recognized in the treatment of several specific tumours
 42   II,     5.  3.  7    |               have been introduced in the treatment of metastatic cancer and
 43   II,     5.  3.  7    |               cancer and thus the cost of treatment is rapidly increasing when
 44   II,     5.  3.  7    |                most cost-effective cancer treatment.~ ~
 45   II,     5.  3.  7    |                 early diagnosis, adequate treatment and end of life care. Organising
 46   II,     5.  3.  7    |            screening, early diagnosis and treatment, as well as research to
 47   II,     5.  3.  7    |                 each patient’s diagnosis, treatment and support;~· Complex interventions
 48   II,     5.  3.  7    |            interventions for diagnosis or treatment require all the necessary
 49   II,     5.  3.  7    |                 care for diagnosis and/or treatment at primary, secondary and
 50   II,     5.  3.  7    |               early detection, diagnosis, treatment and follow-up, and palliative
 51   II,     5.  3.  8    |                each requiring a different treatment.~These are the problems
 52   II,     5.  3.  8    |                  in modern diagnostic and treatment technologies to eliminate
 53   II,     5.  3.  8    |                   to cancer diagnosis and treatment facilities in Europe (especially
 54   II,     5.  3.  8    |                    Give the best possible treatment and care to cancer patients,
 55   II,     5.  3.  8    |            practices regarding diagnosis, treatment, rehabilitation and palliative
 56   II,     5.  3.  8    |                requiring each a different treatment. The long term objective
 57   II,     5.  4.  1    |                 prevention, diagnosis and treatment of diabetes at national
 58   II,     5.  4.  2    |            prevention, identification and treatment of diabetes and particularly
 59   II,     5.  4.  2    |             includes patients receiving a treatment or having been hospitalised.~
 60   II,     5.  4.  2    |               subjects who received laser treatment<3 months after diagnosis
 61   II,     5.  4.  2    |                 Indicator on timely laser treatment of retinopathy is defined
 62   II,     5.  4.  2    |                 retinopathy and had laser treatment within 3 months.~Control
 63   II,     5.  4.  3    |                 was in Scotland where the treatment of elevated cholesterol
 64   II,     5.  4.  3    |                 Indicator on timely laser treatment of retinopathy. For this
 65   II,     5.  4.  4    |                  on retinopathy and laser treatment scarcely available, flagging
 66   II,     5.  4.  6    |                obtained through intensive treatment from the moment of diagnosis
 67   II,     5.  4.  6    |             intervention (early intensive treatment) can modify the progression
 68   II,     5.  4.  6    |     self-education are a separate part of treatment and care for people with
 69   II,     5.  4.  6    |                 prevention, diagnosis and treatment of diabetes in line with
 70   II,     5.  4.  7    |                  to screening, diagnosis, treatment and care. Diabetes, like
 71   II,     5.  4.  7    |              processes, measurement done, treatment, management);~· population (
 72   II,     5.  4.  8    |                   2 diabetes. Occurrence, treatment and prevention seen in a
 73   II,     5.  5.Int    |                  hospitals for short term treatment. There are still many countries
 74   II,     5.  5.Int    |               risk factors, detection and treatment and preliminary evidence
 75   II,     5.  5.Int    |            awareness and better access to treatment options are necessary to
 76   II,     5.  5.Int    |                   lives, needing constant treatment. This creates distress for
 77   II,     5.  5.Int    |                prevented through adequate treatment of psychiatric disorders
 78   II,     5.  5.Int    |                 and earlier detection and treatment of psychiatric illnesses
 79   II,     5.  5.Int    |                   the general population. Treatment with medications for depression,
 80   II,     5.  5.  1    |               about half receive adequate treatment (Alonso et al., 2004b).
 81   II,     5.  5.  1    |                   quality of life, use of treatment and healthcare services.
 82   II,     5.  5.  1    |          Prevalence, incidence, access to treatment and work days lost in mood
 83   II,     5.  5.  1    |                  and low accessibility to treatment were reported to be the
 84   II,     5.  5.  1    |             reported to be the hurdles in treatment of depression (European
 85   II,     5.  5.  1    |                     2008). Disability and treatment of specific mental and physical
 86   II,     5.  5.  2    |                 diagnosis and appropriate treatment is needed in order to ensure
 87   II,     5.  5.  2    |                  guidelines on diagnosis, treatment and psycho-social interventions,
 88   II,     5.  5.  2    |                 improve the diagnosis and treatment of Alzheimer’s disease and
 89   II,     5.  5.  3    |              Health care providers report treatment attendance data (number
 90   II,     5.  5.  3    |                  Health Insurance Centre (treatment attendance data) and in
 91   II,     5.  5.  3    |                  gap between the need for treatment of schizophrenia and access
 92   II,     5.  5.  3    |                  access or utilization of treatment which is connected with
 93   II,     5.  5.  3    |             functioning in the workplace.~Treatment and treatment gaps~During
 94   II,     5.  5.  3    |                  workplace.~Treatment and treatment gaps~During the past decades,
 95   II,     5.  5.  3    |               significant advances in the treatment of schizophrenia. Medications (
 96   II,     5.  5.  3    |                  aged > 15 , the regional treatment gap (median untreated rate =
 97   II,     5.  5.  3    |           inadequacy or unavailability of treatment, people with schizophrenia
 98   II,     5.  5.  3    |          schizophrenia exceeds the direct treatment costs due to remarkable
 99   II,     5.  5.  3    |         associated with schizophrenia, on treatment gaps and costs to cover
100   II,     5.  5.  3    |                  estimates based on first treatment/admission data due to the
101   II,     5.  5.  3    |                   taking into account the treatment gap, the evidence for coding
102   II,     5.  5.  3    |                  and Belgamwar 2006).~The treatment of people with co-morbid
103   II,     5.  5.  3    |              frequent relapses, show poor treatment compliance and are difficult
104   II,     5.  5.  3    |            underestimated.~Evidence based treatment of schizophrenia and treatment
105   II,     5.  5.  3    |            treatment of schizophrenia and treatment gaps.~Treatment options~
106   II,     5.  5.  3    |         schizophrenia and treatment gaps.~Treatment options~The state of the
107   II,     5.  5.  3    |                   state of the art of the treatment of schizophrenia comprises
108   II,     5.  5.  3    |            behavioural therapy. For other treatment approaches, the authors
109   II,     5.  5.  3    |                    Besides optimizing the treatment of patients with schizophrenia,
110   II,     5.  5.  3    |                 diagnosed and appropriate treatment installed (Häfner et al,
111   II,     5.  5.  3    |                 develop. Besides, delayed treatment is more likely to be associated
112   II,     5.  5.  3    |           strategies are needed for both, treatment of prodromal syndromes and
113   II,     5.  5.  3    |            Although a number of prodromal treatment programmes have been initiated
114   II,     5.  5.  3    |                  literature review on the treatment gap in mental health care,
115   II,     5.  5.  3    |                  number of people needing treatment for schizophrenia and the
116   II,     5.  5.  3    |                number of people receiving treatment calculated on service utilization
117   II,     5.  5.  3    |          examination of the extent of the treatment gap in mental health care (
118   II,     5.  5.  3    |             treatments exist), the median treatment gap for schizophrenia (including
119   II,     5.  5.  3    |               receive timely and adequate treatment. This may lead to an increased
120   II,     5.  5.  3    |                  schizophrenia and in its treatment have led to the availability
121   II,     5.  5.  3    |                 from advances achieved in treatment and basic research. Reasons
122   II,     5.  5.  3    |               plenty of evidence that the treatment of schizophrenia should
123   II,     5.  5.  3    |             variability and its effect on treatment. Therefore, there is a need
124   II,     5.  5.  3    |                  factor responsible for a treatment gap is the non-compliance
125   II,     5.  5.  3    |                  within the EUFEST trial, treatment discontinuation over 12
126   II,     5.  5.  3    |                 than in those assigned to treatment with second-generation antipsychotic
127   II,     5.  5.  3    |             insight into the necessity of treatment leads to discontinuation
128   II,     5.  5.  3    |               guidelines on schizophrenia treatment, most of them do not meet
129   II,     5.  5.  3    |             knowledge about schizophrenia treatment and to provide an algorithm
130   II,     5.  5.  3    |               misallocation may lead to a treatment gap as demonstrated in the
131   II,     5.  5.  3    |               findings on unmet needs for treatment among serious cases were
132   II,     5.  5.  3    |               care. However, insufficient treatment is not merely a result of
133   II,     5.  5.  3    |                 2004). While the need for treatment in cases of severe disorders
134   II,     5.  5.  3    |           symptoms emerge and the delayed treatment even after onset of the
135   II,     5.  5.  3    |                 institutions that provide treatment, psychotropic drugs and
136   II,     5.  5.  3    | cost-effectiveness of current and optimal treatment for schizophrenia (Andrews
137   II,     5.  5.  3    |               could be averted by optimal treatment compared to 13% with current
138   II,     5.  5.  3    |                  affordability of optimal treatment within present budgets.~
139   II,     5.  5.  3    |                 of unbiased schizophrenia treatment recommendations. In countries
140   II,     5.  5.  3    |                 for optimal comprehensive treatment.~There are reasons for being
141   II,     5.  5.  3    |       achievements and future progress in treatment and in basic research, and
142   II,     5.  5.  3    |               evaluation of psycho-social treatment strategies, and further
143   II,     5.  5.  3    |              delivery of state-of-the-art treatment in all medical settings;~·
144   II,     5.  5.  3    |                  barriers towards optimal treatment;~· overcome stigma;~· ensure
145   II,     5.  5.  3    | Cost-effectiveness of current and optimal treatment for schizophrenia. Br J
146   II,     5.  5.  3    |              severity, and unmet need for treatment of mental disorders in the
147   II,     5.  5.  3    |                    Saraceno B (2004): The treatment gap in mental health care.
148   II,     5.  5.  3    |                   best practices: current treatment guidelines and protocols
149   II,     5.  5.  3    |               Evidence-based psychosocial treatment practices in schizophrenia:
150   II,     5.  5.  3    |                Interventions in Long-term Treatment in Schizophrenia. psychoneuro
151   II,     5.  5.  3    |              severity, and unmet need for treatment of mental disorders in the
152   II,     5.  5.  3    |                the effectiveness of their treatment~ ~
153   II,     5.  5.  3    |                Epilepsy in remission with treatment is defined by the absence
154   II,     5.  5.  3    |             Epilepsy in remission without treatment (terminal remission) is
155   II,     5.  5.  3    |                 of whom immediately after treatment initiation (Forsgren, 2004).
156   II,     5.  5.  3    |           preceding 5 years regardless of treatment with AEDs (Commission, 1993).
157   II,     5.  5.  3    |              epilepsy undergoing surgical treatment (Harris & Barraclough, 1997).
158   II,     5.  5.  3    |                  complicated and unstable treatment (Jallon, 2004). SUDEP is
159   II,     5.  5.  3    |       schizophrenia (PR 5.8).~ ~Prognosis~Treatment of epilepsy is generally
160   II,     5.  5.  3    |                  idiopathic (3-6 months)~ Treatment stop (ban 3 months)~ II
161   II,     5.  5.  3    |              partial seizures (3 months)~ Treatment stop/change (ban 3 months)~
162   II,     5.  5.  3    |              aspects of the diagnosis and treatment of epilepsy, these instruments
163   II,     5.  5.  3    |           guidelines on the diagnosis and treatment of epilepsy should be disseminated
164   II,     5.  5.  3    |            Aetiology of epilepsy. In: The Treatment of Epilepsy (2nd edition) (
165   II,     5.  5.  3    |             prognosis of epilepsy and its treatment. In: The Treatment of Epilepsy (
166   II,     5.  5.  3    |                and its treatment. In: The Treatment of Epilepsy (2nd edition). (
167   II,     5.  5.  3    |               2001): The dynamics of drug treatment in epilepsy: an observational
168   II,     5.  5.  3    |                  10 is death due to MS.~ ~Treatment~There is no cure for MS,
169   II,     5.  5.  3    |               evidence, early, aggressive treatment is warranted in all patients
170   II,     5.  5.  3    |                and there is evidence that treatment with interferon beta has
171   II,     5.  5.  3    |                 is sometimes used for the treatment of worsening forms of RR-
172   II,     5.  5.  3    |              Framework Directive on Equal Treatment in the Work Place~ ~Council
173   II,     5.  5.  3    |              Framework Directive on equal treatment in the work place is an
174   II,     5.  5.  3    |                 effects of discriminatory treatment towards people with MS in
175   II,     5.  5.  3    |                 effects of discriminatory treatment towards people with multiple
176   II,     5.  5.  3    |                Equal rights and access to treatment, therapies and services
177   II,     5.  5.  3    |            inequalities in the diagnosis, treatment and care of people with
178   II,     5.  5.  3    |                    for example when a new treatment becomes available.~· Escalating
179   II,     5.  5.  3    |                   provide new data on the treatment of clinically isolated syndromes,
180   II,     5.  5.  3    |                  dealing with symptomatic treatment, high quality studies are
181   II,     5.  5.  3    |                  Consensus paper includes treatment guidelines for some of the
182   II,     5.  5.  3(26)|                 effects of discriminatory treatment made to people with multiple
183   II,     5.  5.  3    |                seeks to enhance equity of treatment, access thereto and quality
184   II,     5.  5.  3    |         approaches towards the diagnosis, treatment and management of MS. More
185   II,     5.  5.  3    |                 the European Committee in Treatment and Research in Multiple
186   II,     5.  5.  3    |              Toyka KY (2006): Symptomatic Treatment of Multiple Sclerosis. Multiple
187   II,     5.  5.  3    |              pharmacological and surgical treatment options available, the disease
188   II,     5.  5.  3    |                least 17 years of levodopa treatment (Uitti et al, 1993).~ ~Comorbidity~
189   II,     5.  5.  3    |              healthy population. Although treatment options for PD have increased
190   II,     5.  5.  3    |              aspects of the diagnosis and treatment of PD, these instruments
191   II,     5.  5.  3    |                   not receive appropriate treatment. Identifying these individuals
192   II,     5.  6.  2    |               guide to the prevention and treatment of musculoskeletal conditions
193   II,     5.  6.  3    |             earliest stage to allow early treatment. Recently, recommendations
194   II,     5.  6.  3    |                   Course, 2008).~ ~Modern treatment is effective in controlling
195   II,     5.  6.  3    |               long-term disability. Early treatment aimed at controlling disease
196   II,     5.  6.  3    |             aggressive approaches towards treatment with less effective therapeutic
197   II,     5.  6.  3    |                 current therapies. Modern treatment is effective at controlling
198   II,     5.  6.  3    |                  disability, whilst early treatment aimed at controlling disease
199   II,     5.  6.  4    |                 Europeans under long-term treatment give as major reason muscle,
200   II,     5.  6.  6    |                and medical perceptions of treatment in eight European countries.
201   II,     5.  7.  1    |                undisputable evidence that treatment can prevent or delay kidney
202   II,     5.  7.  1    |                   73 m2 )~ICD 9 CM Code~ ~Treatment~ ~1~Kidney damage~with normal
203   II,     5.  7.  2    |                   patients the changes in treatment and the date and cause of
204   II,     5.  7.  3    |             investigators to suggest that treatment strategies for the prevention
205   II,     5.  7.  3    |             investigators to suggest that treatment strategies for the prevention
206   II,     5.  7.  5    |              drugs should be used for the treatment of neoplasia, screening
207   II,     5.  7.  5    |                   reporting on quality of treatment is still not compulsory.~·
208   II,     5.  7.  5    |        potentially life-saving advice and treatment. CKD receives 27 points
209   II,     5.  7.  5    |          concerning the provision of ESRD treatment throughout Austria have
210   II,     5.  7.  5    |                 quality assurance in ESRD treatment. The Health Plan found its
211   II,     5.  7.  5    |               were 464 pmp under dialysis treatment. The registry of patients (
212   II,     5.  7.  6    |                patients, whereas costs of treatment are lower, it is important
213   II,     5.  7.  7    |                albuminuria and subsequent treatment with an ACE inhibitor to
214   II,     5.  7.  7    |                Detection, Evaluation, and Treatment of High Blood Pressure:
215   II,     5.  7.  7    |                Detection, Evaluation, and Treatment of High Blood Pressure OQI
216   II,     5.  8.  3    |               impact or require different treatment for patients with COPD (
217   II,     5.  8.  3    |            considering the total cost for treatment of 40+ year patients, 10%
218   II,     5.  8.  3    |             patients, 10% was directed to treatment of COPD (Bilde et al, 2007).
219   II,     5.  8.  3    |               these costs were due to the treatment of COPD as primary diagnosis,
220   II,     5.  8.  3    |                   37 days and the cost of treatment per patient was 1.017 Euro.
221   II,     5.  8.  3    |                   length of stay, cost of treatment) were higher for COPD than
222   II,     5.  8.  7    |           Standards for the diagnosis and treatment of patients with COPD: a
223   II,     5.  8.  7    |                from hospital: the role of treatment and co-morbidity. Respir
224   II,     5.  9. FB    |                thus, prompt diagnosis and treatment are required to stop the
225   II,     5.  9. FB    |                   do not receive adequate treatment. Allergic diseases are considered “
226   II,     5.  9. FB    |                  problem of diagnosis and treatment compliance by health professionals
227   II,     5.  9. FB    |                   effective diagnosis and treatment. Prevention requires a more
228   II,     5.  9. FB    |                  better implementation of treatment guidelines requires more
229   II,     5.  9. FB    |             individuals to begin an early treatment. In Europe,,allergic patients
230   II,     5.  9.  1    |                spontaneously or following treatment. AR is associated with impairments
231   II,     5.  9.  1    |                   combined diagnostic and treatment strategy should be used
232   II,     5.  9.  3    |                 diagnosis, 25100 received treatment from general practitioner,
233   II,     5.  9.  3    |                     whilst emergency room treatment was 14-18%. Nevertheless,
234   II,     5.  9.  3    |                   85 days and the cost of treatment per patient was 750.18 Euro (
235   II,     5.  9.  3    |                   length of stay, cost of treatment) was higher for COPD than
236   II,     5.  9.  5    |              guidelines for diagnosis and treatment of proven efficacy. Prevention
237   II,     5.  9.  5    |                  better implementation of treatment guidelines requires more
238   II,     5.  9.  5    |                  methods of diagnosis and treatment strategies. The emphasis
239   II,     5.  9.  5    |                gain a better awareness of treatment targets.~New anti-allergic
240   II,     5.  9.  5    |                and for a final diagnosis, treatment and clinical monitoring
241   II,     5.  9.  6    |                 the choice of appropriate treatment (WHO, 1952).~ ~GINA guidelines
242   II,     5.  9.  6    |               worldwide for what concerns treatment and evidence-based recommendations (
243   II,     5.  9.  6    |               rhinitis and make effective treatment for rhinitic symptoms available
244   II,     5. 10.  4    |             beyond the cost of diagnosis, treatment of clinical manifestations,
245   II,     5. 10.  7    |               approaches to diagnosis and treatment of celiac disease: An evolving
246   II,     5. 11.  3    |            regarding the most appropriate treatment that can prevent lifelong
247   II,     5. 11.  6    |                   could, in turn, improve treatment and lead to a more effective
248   II,     5. 12.  3    |                  endoscopic banding, drug treatment and transjugular intraheatic
249   II,     5. 12.  6    |                    a contribution towards treatment and prognosis of cirrhosis
250   II,     5. 12.  6    |                  increase its role in the treatment and prognosis of cirrhosis,
251   II,     5. 14.  1    |               rates and more unmet dental treatment needs than their higher
252   II,     5. 14.  3    |               rates and more unmet dental treatment needs than their higher
253   II,     5. 14.  3    |                 same populations for whom treatment is apparently difficult
254   II,     5. 14.  6    |                professionals and limiting treatment costs have also to be taken
255   II,     5. 14.  7    |                 missing teeth. Prosthetic treatment is not uniquely limited
256   II,     5. 14.  7    |                 practice in dentistry and treatment decision making is absolutely
257   II,     5. 15.  4    |                 prevention, diagnosis and treatment of RD and to provide a forum
258   II,     5. 15.  4    |                    prevention, diagnosis, treatment, care, and research for
259   II,     5. 15.  5    |                 access for EU citizens to treatment requiring a particular concentration/
260   II,     6.  3.  1    |               hospital-acquired infection treatment are included. Also, a recent
261   II,     6.  3.  3    |                  access to antiretroviral treatment likely to be less than in
262   II,     6.  3.  3    |                 need to receive life-long treatment, care and support. Currently
263   II,     6.  3.  4    |                   infectious patients and treatment for at least six months
264   II,     6.  3.  4    |                   antibiotics. Inadequate treatment may result in failure of
265   II,     6.  3.  6    |                   do not require any drug treatment, invasive infections do
266   II,     6.  3.  7    |              health concern in Europe. No treatment or vaccine is currently
267   II,     6.  3.  7    |               ticks. There is no specific treatment or vaccine available, and
268   II,     6.  3.  7    |                  blood or body fluids. No treatment or vaccine is available
269   II,     6.  3.  7    |                for the virus. No specific treatment is available for yellow fever,
270   II,     6.  4.  5    |                  dose and duration of the treatment and training on hygiene
271   II,     7.  3.  1    |                  18 300 000 Other medical Treatment~ ~· This corresponds to
272   II,     7.  4.  2    |              elderly will receive medical treatment due to an injury each year,
273   II,     7.  6        |                   improvements of medical treatment ( e.g. trauma and emergency
274   II,     8.  1.  5    |                   right to dignity, equal treatment, independent living and
275   II,     8.  2.  1    |                   conditions do not begin treatment soon after birth. Parents
276   II,     8.  2.  1    |               those who received standard treatment alone. They suggest that
277   II,     8.  2.  1    |             identification of disease and treatment availability contribute
278   II,     8.  2.  1    |              special diet. If the correct treatment is started soon enough after
279   II,     8.  2.  2    |             direct costs are those of the treatment of eye diseases, including
280   II,     9            |               primary prevention as well. Treatment effects appear to be similar
281   II,     9.  1.  1    |           pregnancies following fertility treatment~R: Distribution of timing
282   II,     9.  1.  1    |                   a detailed and specific treatment of congenital malformations.~ ~
283   II,     9.  1.  2    |             concerns access to preventive treatment and rehabilitative research,
284   II,     9.  1.  2    |               pregnancy d) the quality of treatment for congenital anomalies (
285   II,     9.  2.  2    |                 and to facilities for the treatment of illness and rehabilitation
286   II,     9.  2.  3(2) |                  diagnostic labelling and treatment by doctors between populations.
287   II,     9.  2.  3    |              system in order to close the treatment gap in this area. The EU
288   II,     9.  3.  1    |                best form of diagnosis and treatment. For instance, erectile
289   II,     9.  3.  1    |                  risk factors, detection, treatment and preliminary evidence
290   II,     9.  3.  1    |                  hospitals for short term treatment. There are still many countries
291   II,     9.  3.  1    |                   lives, needing constant treatment. This creates distress for
292   II,     9.  3.  1    |                   for further testing and treatment (Arber, 2006).~ ~Because
293   II,     9.  3.  1    |          diagnosed by ultrasound scan and treatment has a high success rate.
294   II,     9.  3.  1    |               with diabetes under medical treatment grew by 43% from 1988 to
295   II,     9.  3.  1    |                  more effective than drug treatment in reducing the incidence
296   II,     9.  3.  1    |                   which may influence the treatment and severity of the health
297   II,     9.  3.  1    |                  in patient selection for treatment or intervention for osteoporosis,
298   II,     9.  3.  1    |          individuals at greatest need for treatment still remains a problem.
299   II,     9.  3.  1    |          osteoporosis and may not receive treatment to prevent further loss
300   II,     9.  3.  1    |            fractures and their (surgical) treatment being considerably greater
301   II,     9.  3.  1    |         undergoing glucocorticoid steroid treatment for lung disease (Lim &
302   II,     9.  3.  1    |                   Fitzpatrick, 2004); the treatment of prostate cancer, which
303   II,     9.  3.  1    |           initiating Androgen Replacement Treatment (ART). In case of unclear
304   II,     9.  3.  1    |               primary prevention as well. Treatment effects appear to be similar
305   II,     9.  3.  1    |                   Advances in Psychiatric Treatment 14: 256-262~ ~Braun, M.,
306   II,     9.  3.  1    |    gonadotropin-releasing hormone agonist treatment for prostate carcinoma.
307   II,     9.  3.  2    |                           Infertility and treatment of infertility~Advances
308   II,     9.  4.  3    |            awareness and better access to treatment options are needed to prevent,
309   II,     9.  4.  3    |                   more effective forms of treatment for CHD, leading to more
310   II,     9.  4.  3    |                  Possible causes are that treatment is not as good as that given
311   II,     9.  4.  3    |                may not tolerate intensive treatment, or doctors do not focus
312   II,     9.  5.  1    |                   history, diagnosis, and treatment of disease between men and
313   II,     9.  5.  1    |                risk factors, symptoms and treatment of cardiovascular diseases
314   II,     9.  5.  1    |                  not receive as effective treatment or health information as
315   II,     9.  5.  1    |                respond differently to the treatment they receive. Most research
316   II,     9.  5.  1    |                  Research on the types of treatment that are best for women
317   II,     9.  5.  3    |                   access to screening and treatment, may adversely influence
318   II,     9.  5.  3    |                bias can also occur in the treatment of psychological disorders.
319   II,     9.  5.  3    |                   30 000). In comparison, treatment for the perpetrator costs
320   II,     9.  5.  3    |                problem drinkers receiving treatment cite marital conflict as
321   II,     9.  5.  3    |                   support rather than the treatment per se. Women are more likely
322   II,     9.  5.  4    |                   opportunities and equal treatment of men and women in matters
323  III,    10.  1.  3    |                   alcohol use, alcoholism treatment, and relapse. Alcohol Res
324  III,    10.  1.  3    |                  1994): The diagnosis and treatment of social phobia and alcohol
325  III,    10.  2.  1    |                   the costs linked to the treatment of reproductive problems,
326  III,    10.  2.  1    |               phases of tobacco addiction treatment, not only as a first-line
327  III,    10.  2.  1    |                wide range of psychosocial treatment options, including counselling
328  III,    10.  2.  1    |                  to raise awareness about treatment possibilities.~ ~Curbing
329  III,    10.  2.  1    |           information, warning labels and treatment for those wanting to quit
330  III,    10.  2.  1    |           warnings and tobacco dependence treatment subscales was recorded.
331  III,    10.  2.  1    |                    warning labels (5) and treatment for those wanting to quit
332  III,    10.  2.  1    |       alcohol-related. Alcohol alters the treatment course of injured patients
333  III,    10.  2.  1    |           licensed premises.~ ~Advice and treatment~ ~Healthcare-based interventions
334  III,    10.  2.  1    |               wide variety of specialized treatment approaches have been evaluated,
335  III,    10.  2.  1    |                  than those not receiving treatment. Moreover, for the average
336  III,    10.  2.  1    |                   Genomics, mechanism and treatment of addiction~http ~ ~European
337  III,    10.  2.  1    |              Drugs and Drug Addiction~TDI~Treatment demand indicator~ ~ ~
338  III,    10.  2.  1    |                users; (v) demand for drug treatment), but also other important
339  III,    10.  2.  1    |        drug-related problems (prevention, treatment, harm reduction, etc.),
340  III,    10.  2.  1    |                problem drug users (PDUs), treatment demands and drug overdoses
341  III,    10.  2.  1    |             frequently a complication for treatment.~ ~Morbidity: HIV & Hepatitis
342  III,    10.  2.  1    |                 near future and access to treatment will be a critical issue.~ ~
343  III,    10.  2.  1    |                the last reporting year.~ ~Treatment demand17~ ~In many countries,
344  III,    10.  2.  1    |                   the main drug for which treatment is seeked. Of the total
345  III,    10.  2.  1    |               total approximately 326 000 treatment requests reported in 2005,
346  III,    10.  2.  1    |                the relative proportion of treatment demands made by non-opioid
347  III,    10.  2.  1    |              clients is increasing in the Treatment Demand Indicator (TDI) data
348  III,    10.  2.  1    |                  of new clients demanding treatment for opioid use has been
349  III,    10.  2.  1    |                 new drugs clients seeking treatment went down from 64% to 32%.
350  III,    10.  2.  1    |             proportion of clients seeking treatment for primary cannabis use
351  III,    10.  2.  1    |                   the reason for entering treatment in Europe. From 1999 to
352  III,    10.  2.  1    |                  of new clients demanding treatment for cocaine use more than
353  III,    10.  2.  1    |               data on drug users entering treatment for primary cocaine use
354  III,    10.  2.  1    |             overall number of demands for treatment related to the use of amphetamines
355  III,    10.  2.  1    |                 reason for attending drug treatment in the EU.~ ~Figure 10.2.
356  III,    10.  2.  1    |                   of new clients entering treatment, subdivided by primary drug
357  III,    10.  2.  1(17)|         methodological information about ‘Treatment Demand Indicatorplease
358  III,    10.  2.  1    |             demand reduction (prevention, treatment and harm reduction) interventions
359  III,    10.  2.  1    |                   outpatient substitution treatment and harm reduction interventions
360  III,    10.  2.  1    |                received drug substitution treatment in the EU Member States
361  III,    10.  2.  1    |                  coverage of substitution treatment could be made19, results
362  III,    10.  2.  1    |              opiate users undergoing such treatment. Substitution treatment
363  III,    10.  2.  1    |                   treatment. Substitution treatment adds to other types of treatments
364  III,    10.  2.  1    |                  inpatient and outpatient treatment and detoxification. Social
365  III,    10.  2.  1    |                interventions (prevention, treatment, social rehabilitation,
366  III,    10.  2.  1    |                   studied and prevention, treatment and harm reduction intervention
367  III,    10.  2.  1    |                   have developed accurate treatment modalities and assistance
368  III,    10.  2.  1    |               among drug users, long-term treatment outcomes and other subjects
369  III,    10.  2.  1    |                 integrated prevention and treatment of chronic non-communicable
370  III,    10.  2.  1    |                 prevention, diagnosis and treatment of nutrition-related diseases).~·
371  III,    10.  2.  3    |                   high, a pharmacological treatment must be considered. Desired
372  III,    10.  3.  2    |                  and communal waste water treatment plants, recycling, and (
373  III,    10.  3.  2    |           difference is due to obligatory treatment of furniture in the UK with
374  III,    10.  3.  3    |                   do not require any drug treatment, invasive infections do
375  III,    10.  3.  4    |                   improved prevention and treatment of winter infections have
376  III,    10.  3.  4    |          surveillance, water analysis and treatment, health education and information
377  III,    10.  4.  1    |                 materials, chemicals from treatment of furniture and decorations,
378  III,    10.  4.  2    |      polyacrylamide is used in wastewater treatment and paper and pulp processing.
379  III,    10.  4.  3    |                 quality control and water treatment mechanism is in place and
380  III,    10.  4.  3    |                   systems including water treatment and quality control. However,
381  III,    10.  4.  3    |              usually consumed without any treatment.~ ~In certain parts of the
382  III,    10.  4.  3    |                   systems including water treatment and quality control. In
383  III,    10.  4.  3    |                  without any purification treatment. For example, in a sparsely
384  III,    10.  4.  3    |                    at http ~ ~Waste water treatment~ ~The European Union is
385  III,    10.  4.  3    |                   connected to wastewater treatment facilities between 1980
386  III,    10.  4.  3    |                   connected to wastewater treatment facilities in 2003. There
387  III,    10.  4.  3    |                   connected to wastewater treatment facilities. In Southern
388  III,    10.  4.  3    |                   connected to wastewater treatment facilities, selected European
389  III,    10.  4.  3    |         contamination through appropriate treatment processes and the prevention
390  III,    10.  4.  3    |               Waste water and waste water treatment is regulated by EU Council
391  III,    10.  4.  3    |         discharges from urban waste water treatment plants to sensitive areas
392  III,    10.  4.  3    |                  insufficient waste water treatment. New potential pollutants
393  III,    10.  4.  3    |            Current sewage and waste water treatment processes are not designed
394  III,    10.  4.  3    |                 with monitoring and local treatment at household level significantly
395  III,    10.  4.  5    |                investments in waste water treatment facilities, bathing water
396  III,    10.  4.  5    |                  due to inadequate sewage treatment and pollution from animal
397  III,    10.  4.  5    |                  due to inadequate sewage treatment and pollution from animal
398  III,    10.  4.  5    |                   inadequate disposal and treatment of municipal and industrial
399  III,    10.  4.  5    |                inappropriate disposal and treatment of waste from municipal
400  III,    10.  4.  5    |                   are in need of remedial treatment. These estimates have increased
401  III,    10.  4.  5    |                activities, as well as the treatment and disposal of waste, remain
402  III,    10.  4.  5    |                    or exported for proper treatment.~ ~References~ ~European
403  III,    10.  5.  1    |                   requiring uninterrupted treatment such as TB and HIV are often
404  III,    10.  6.  1    |          health promotion, prevention and treatment measures.~ ~
405  III,    10.  6.  2    |                hypertension detection and treatment, surgical interventions
406  III,    10.  6.  2    |           incidence and prevalence rates, treatment and cure rates, and access
407   IV,    11.  1.  1    |                    disease prevention and treatment, and quality of life of
408   IV,    11.  1.  3    |        disaggregating access to effective treatment from broader lifestyle changes
409   IV,    11.  1.  4    |                   the same thing as equal treatment or utilization (Mooney et
410   IV,    11.  1.  5    |                   the extent to which the treatment corresponds to the needs
411   IV,    11.  1.  5    |                 may reduce disparities in treatment across physicians as well
412   IV,    11.  1.  5    |              developed to facilitate drug treatment decision-making by clinicians (
413   IV,    11.  1.  5    |                   are based on results of treatment as opposed to the treatment
414   IV,    11.  1.  5    |               treatment as opposed to the treatment levels themselves. Examples
415   IV,    11.  1.  5    |               simple ignorance, lapses in treatment delivery, miscommunication,
416   IV,    11.  1.  6    |                  flat sum for a patient’s treatment according to their specific
417   IV,    11.  1.  6    |                   minimize costs within a treatment group (Busse et al, 2006).~ ~
418   IV,    11.  1.  6    |                 about outlier cases (i.e. treatment episodes with much higher
419   IV,    11.  2.  1    |              curing illness and providing treatment of injury). There seems
420   IV,    11.  2.  1    |                 addition to diagnosis and treatment. Similarly, the Chronic
421   IV,    11.  5.  1    |                   the most cost-effective treatment for end-stage renal failure,
422   IV,    11.  5.  1    |                  it is the only available treatment. About 250.000 individuals
423   IV,    11.  5.  1    |                future may offer practical treatment for other unmet medical
424   IV,    11.  5.  6    |                 and blood used in medical treatment. EU Directives have been
425   IV,    11.  6.  2    |                 cost are unable to obtain treatment, cannot access the same
426   IV,    11.  6.  4    |                  Best practice and latest treatment methods for diseases and
427   IV,    11.  6.  5    |                clinical guidelines in the treatment of diabetes mellitus in
428   IV,    12.  1        |              would otherwise have gone on treatment and burdened the economy.
429   IV,    12.  2        |                   the CVD risk increases; treatment targets for LDL cholesterol
430   IV,    12.  2        |                 life-long pharmacological treatment with drugs must be considered.~ ~
431   IV,    12.  2        |               early detection, diagnosis, treatment and follow-up, and palliative
432   IV,    12.  2        |                 prevention, screening and treatment of the disease in Europe.~ ~
433   IV,    12.  2        |                 too advanced for curative treatment, thus improving the quality
434   IV,    12.  2        |              diagnosis, access to optimal treatment and investment in health
435   IV,    12.  2        |                 early diagnosis, adequate treatment and end of life care. It
436   IV,    12.  2        |                obtained through intensive treatment from diagnosis onwards.
437   IV,    12.  2        |             intervention (early intensive treatment) can modify the progression.
438   IV,    12.  2        |             timely initiation of adequate treatment. The WHO 2003 report defines
439   IV,    12.  2        |               phases of tobacco addiction treatment, not only as a first-line
440   IV,    12.  2        |                wide range of psychosocial treatment options, including counseling
441   IV,    12.  2        |           licensed premises.~ ~Advice and treatment~ ~Healthcare-based interventions
442   IV,    12.  2        |               wide variety of specialized treatment approaches have been evaluated,
443   IV,    12.  2        |                  than those not receiving treatment. Further, for the average
444   IV,    12.  2        |                   Genomics, mechanism and treatment of addiction~http European
445   IV,    12.  3        |                 an easy access to medical treatment when travelling, social
446   IV,    12.  3        |               coverage abroad, more equal treatment of women and men, fight
447   IV,    12.  4        |                    research on health and treatment including public health
448   IV,    12. 10        |             population through screening, treatment and rehabilitation of concrete
449   IV,    12. 10        |             selected conditions and their treatment is offered by the Institute
450   IV,    12. 10        |                   of the Working~Group on Treatment of Under 18~year olds Presenting
451   IV,    12. 10        |                   year olds Presenting to Treatment~Services with Serious Drug
452   IV,    12. 10        |                 Ireland - Evaluating Drug Treatment Effectiveness) study.~ ~
453   IV,    12. 10        |                   care”~High~The National Treatment Purchase Fund (NTPF) which
454   IV,    12. 10        |                  and screening through to treatment services, supportive and
455   IV,    12. 10        |                 Enforcement for the equal treatment of men and women, concerning
456   IV,    12. 10        |                 prevention, diagnosis and treatment of mental and affective
457   IV,    12. 10        |             Circular letter on diagnosis, treatment and control of AHT (Arterial
458   IV,    12. 10        |                  dead and needing medical treatment) in different environments~
459   IV,    13.  4        |       implementing the principle of equal treatment between persons irrespective
460   IV,    13.  4        |               general framework for equal treatment in employment and occupation.~
461   IV,    13.  5        |                  be required for hospital treatment abroad and must be given
462   IV,    13.  7        |             become a common and effective treatment for end-stage renal, liver,
463   IV,    13.  7.  5    |                  the provision of care or treatment or the management of health
464   IV,    13.  7.  5    |                  the provision of care or treatment or the management of health-care
465   IV,    13.  9        |         Incentives and Regulations in the Treatment of Ageing-related Diseases,